Clinical trials: Respiratory Infection Prevention
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04352608
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs).
- Trial name
- NCT04507256
- Testing
- AZD7442
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Respiratory Syncytial Virus Infection, Premature Birth
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial…
- Conditions
- Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease
- Trial name
- NCT01006629
- Testing
- palivizumab
- Where
- 19 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
COVID-19 Prevention
Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian…
- Trial name
- NCT04640233
- Testing
- Gam-COVID-Vac
- Where
- 23 sites in India
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Influenza
Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine
This is a single blind, reference drug controlled, one center viral immunogenicity and tolerability study of FluvalAB FL-K-004 Trivalent Influenza Vaccine with 6 μg HA/strain/dos antigen content to assess immunogenicity and…
- Trial name
- NCT00778297
- Testing
- Vaccination with FluvalAB FL-K-004 trivalent flu vaccine, Vaccination with FluvalAB trivalent influenza vaccine
- Where
- Hungary
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
COVID - 19
Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults
This is a randomized (4:1) Phase 1 b safety trial in adults who have completed their full COVID-19 vaccination schedule at least 30 days prior to study entry.
- Trial name
- NCT04672291
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Oncovir, Inc.
Common Cold, Healthy
Efficacy Study of A Lotion to Prevent Common Colds
The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands.
- Trial name
- NCT00993759
- Testing
- 3804-250A
- Where
- United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- The Dial Corporation
COVID-19, SARS-CoV-2
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- SUPERNOVA (NCT05648110)
- Testing
- AZD5156 (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort)
- Where
- 215 sites in United States, Australia and 16 more
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Covid19, Prophylaxis
Mesenchymal Stem Cells for the Treatment of COVID-19
This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the…
- Trial name
- NCT04573270
- Testing
- PrimePro
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
Respiratory Tract Infections
PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections
Primary To evaluate the efficacy of Pulmonaron in the decrease of interleukin-4/interferon gamma after second period of treatment Secondary To evaluate the efficacy of Pulmonarom in the prevention of upper respiratory tract…
- Trial name
- NCT00599417
- Testing
- Bacterial Lysates
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Sanofi
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal…
- Trial name
- MI-MA182 (NCT00677820)
- Testing
- Trivalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
Covid-19, SARS-CoV2
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia.
- Trial name
- COVA (NCT04472728)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 238 people
- Sponsor
- Biophytis
Streptococcus Pneumoniae Vaccines
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis.
- Trial name
- NCT00307008
- Testing
- Pneumovax 23™
- Where
- 5 sites in Sweden
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine
This study is a randomized, placebo-controlled and open design, phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.
- Trial name
- NCT04953325
- Testing
- Inactivated COVID-19 Vaccine, 23-valent pneumococcal polysaccharide vaccine, Inactivated Hepatitis A Vaccine
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Prophylaxis Invasive Pneumococcal Diseases and Pneumonia
Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population
As the licensed Pneumovax 23™ vaccine is not always satisfactory in elderly subjects, the safety and the immune response of the new investigational pneumococcal protein vaccine is evaluated in healthy elderly population.
- Trial name
- NCT00307528
- Testing
- Pneumococcal vaccine GSK513026, Pneumovax 23™
- Where
- Belgium
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons
The purpose of this study is to determine the immunogenicity and tolerability of Fluval AB trivalent influenza vaccine in adults and elderly people.
- Trial name
- NCT01404182
- Testing
- Vaccination with Fluval AB influenza vaccine
- Where
- 2 sites in Hungary
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Prophylaxis of Avian Influenza
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination
- Trial name
- NCT00537524
- Testing
- H5N1 Influenza Vaccine
- Where
- Finland
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Diphtheria, Tetanus
Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine
The objective of this study is to compare the Safety and Immunogenicity of a mixed sequence of 2 different pentavalent vaccines (Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib combination Vaccines) with single sequence of…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00674908
- Testing
- Shan 5, Easy Five
- Where
- 3 sites in India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Shantha Biotechnics Limited